Photo:
utswmed.org
Mar 5, 2026, 15:51
Samer Al Hadidi: Cytopenias and Infection Risk With BCMA-Directed Bispecific Antibodies
Samer Al Hadidi, Associate Professor at UT Southwestern Medical Center, shared a post on LinkedIn:
“The Overlooked Burden of Cytopenias With BCMA-Directed Bispecific Antibodies
Hematologic toxicity is underappreciated:
- 87% of pts: grade 3-4 lymphopenia
- 55% grade 3-4 neutropenia (65% with teclistamab)
- 74% required dose interruptions
- 54.5% needed G-CSF
This is likely one of the important causes of higher grade infections with those agents.
We need to think about preventive strategies given the high efficacy of those agents.”
Stay updated with Hemostasis Today.
-
Jun 11, 2026, 23:56Francesco Tannura: Here’s a Graphical Summary of Our Latest Work about CAT
-
Jun 11, 2026, 23:38Why the New 2026 CKM Syndrome Guideline Changes Everything for Chronic Disease Prevention – American College of Cardiology
-
Jun 11, 2026, 23:04ISTH Members Elect the Council Class of 2032
-
Jun 11, 2026, 22:45Tsigereda Bekele: Deep Vein Thrombosis vs Pulmonary Embolism
-
Jun 11, 2026, 22:30Rehan Khan Explores Streptokinase
-
Jun 11, 2026, 16:46Moaz Abouelmagd: Key Findings from a Large Network Meta-Analysis of IV Thrombolytics in Acute Ischemic Stroke
-
Jun 11, 2026, 16:37Wolfgang Miesbach: From Failed Intravitreal Trials to Real Benefit – Subretinal AAV8 Gene Therapy in Pediatric X-Linked Retinoschisis
-
Jun 11, 2026, 16:34Joao Mariano Pego: Advancing Coagulation Diagnostics Through Standardized Thrombin Generation
-
Jun 11, 2026, 16:33Ifeanyichukwu Ifechidere: Nobody Talks About Thrombosis in Sickle Cell Disease